Medication info
Neurorbalin Capsule 75mg (Pregabalin)

Neurorbalin Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
Hard capsule with reddish brown upper part and white lower part filled with white or light yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201901933 · Approved 2019.03.29 · Insurance code 625201850

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medication, as pregabalin, orally in 2 divided doses, regardless of food. As this medication is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. Peripheral neuropathic pain, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Fibromyalgia: The recommended dose is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. If treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose For women, multiply the result obtained using the above calculation by 0.85. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily The total daily dose (mg/day) should be divided as specified in the dosing regimen. A supplemental dose refers to an additional single dose. Dose adjustment is not required in patients with hepatic impairment. Older adults (65 years of age or older): Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients 12 ~17 years of age: Use is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for epilepsy with or without secondary generalized symptoms. It is used to help relieve the symptoms of fibromyalgia. It is utilized for symptom improvement in various neurological disorders.

How to take

Adult dose

Administer the total daily dose of this medication, as pregabalin, orally in 2 divided doses, regardless of food. As this medication is primarily excreted by the kidneys, the dose must be adjusted in patients with impaired renal function. Peripheral neuropathic pain, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy, adults: An initial dose of 150 mg per day may be administered. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Fibromyalgia: The recommended dose is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. If treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose For women, multiply the result obtained using the above calculation by 0.85. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily The total daily dose (mg/day) should be divided as specified in the dosing regimen. A supplemental dose refers to an additional single dose. Dose adjustment is not required in patients with hepatic impairment. Older adults (65 years of age or older): Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients 12 ~17 years of age: Use is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so report any mood changes or symptoms of depression to your healthcare provider immediately while taking it. Do not use if allergic to any of the ingredients in this medication, and patients with lactose intolerance should also avoid it. Diabetic patients should be cautious as weight gain after taking this medication may require adjustment of their blood sugar control medication. If symptoms of angioedema occur, stop taking the medication immediately and consult your healthcare provider. Elderly patients should be especially cautious during initial dosing due to the risk of falls from dizziness and drowsiness. This medication can cause visual disturbances such as blurred vision or changes in eyesight, and patients should inform their healthcare provider if symptoms occur. Patients with a history of drug abuse may be at increased risk for misuse of this medication, requiring careful use. Patients with impaired renal function may need dose adjustments; consult with your healthcare provider regarding this. Concomitant use of this medication and opioid analgesics may increase the risk of central nervous system depression, so caution is advised. During early pregnancy, this medication may affect the fetus, and women who are pregnant or planning to become pregnant should consult with their healthcare provider. Patients experiencing dizziness or drowsiness should avoid driving or operating hazardous machinery. Patients experiencing severe skin rash or allergic symptoms should stop taking the medication immediately and inform their healthcare provider. In case of overdose, symptoms such as confusion, drowsiness, depression, or seizures may occur, requiring caution, and treatment such as dialysis may be necessary. Keep out of the reach of children, and avoid transferring to other containers. This medication is not recommended for breastfeeding women; a decision should be made considering breastfeeding status and the benefits of treatment. Elderly patients may require dose adjustments due to delayed drug elimination caused by decreased renal function.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 219 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • relief
  • decreased libido
  • insomnia
  • depersonalization
  • hyperesthesia
  • restlessness
  • anxiety
  • mood instability
  • emotional decline
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disturbances
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tics
  • decreased reflexes
  • motor disturbances
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremors of activity
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing impairment
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual impairment
  • visual field loss
  • photophobia
  • dry eyes
  • ocular swelling
  • reduced visual acuity
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbances
  • falling
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased potassium levels
  • weight loss
  • increased blood creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusional state
  • depression
  • agitation
  • restlessness
  • exacerbation of spasms
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool
  • fatigue
  • weakness
  • gait disturbances
  • decreased libido
  • sleep disorders
  • insomnia
  • ataxia
  • dysarthria
  • sensory abnormalities
  • memory impairment
  • attention deficit

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsule with reddish brown upper part and white lower part filled with white or light yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.